Analysts have been eager to weigh in on the Healthcare sector with new ratings on Novavax (NVAX – Research Report) and Verrica Pharmaceuticals (VRCA – Research Report).
Novavax (NVAX)
TD Cowen analyst Brendan Smith maintained a Hold rating on Novavax today and set a price target of $8.00. The company’s shares closed last Thursday at $6.78, close to its 52-week low of $5.61.
According to TipRanks.com, Smith is ranked #6936 out of 8601 analysts.
Novavax has an analyst consensus of Hold, with a price target consensus of $15.75.
See Insiders’ Hot Stocks on TipRanks >>
Verrica Pharmaceuticals (VRCA)
In a report released today, Serge Belanger from Needham maintained a Buy rating on Verrica Pharmaceuticals, with a price target of $8.00. The company’s shares closed last Thursday at $3.27.
According to TipRanks.com, Belanger is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Verrica Pharmaceuticals with a $12.25 average price target, implying a 240.3% upside from current levels. In a report released today, TD Cowen also maintained a Buy rating on the stock with a $15.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on NVAX:
- Novavax (NASDAQ:NVAX) Gains on Q3 Beat
- Novavax Reports Third Quarter 2023 Financial Results and Operational Highlights
- Options Volatility and Implied Earnings Moves Today, November 09, 2023
- Largest borrow rate increases among liquid names
- Novavax’s Nuvaxovid XBB.1.5 dispersion receives approval in Europe
